Affibody’s Nomination Committee for the 2025 Annual General Meeting

News

January 7, 2025

Stockholm, Sweden, January 7, 2025. Affibody Medical AB (publ) today announced the composition of the Nomination Committee for the 2025 Annual General Meeting (AGM) to be held on May 27, 2025.

The Nomination Committee, which has been appointed in accordance with the guidelines adopted by the Annual General Meeting on May 19, 2022, comprises the following members:

Malte St Cyr Ohm, Chair of the Nomination Committee, appointed by Duba AB.
Mathias Uhlén, appointed by himself and closely related parties.
Per Lorange, appointed by S. Ugelstad Invest AS.

Robert Burns, Chair of the Board of Directors, will co-opt to the Nomination Committee.

The Committee's assignment is to present proposals regarding Chairman and other members of the Board, as well as remuneration to the Board´s members, to the AGM. The Nomination Committee shall also submit proposals for appointment and remuneration of auditors. The guidelines for the Nomination committee are available on www.affibody.com.

About Affibody

Affibody is a clinical stage integrated biopharmaceutical company with a broad product pipeline focused on developing innovative bi- and multi-specific next generation biopharmaceutical drugs based on its unique proprietary technology platform, Affibody® molecules.

Through its validated business model, the company has a proven capability of identifying and prioritizing strategic projects in a timely and de-risked way. Affibody has established several partnerships for the development and commercialization of its innovations with international pharmaceutical companies.

Affibody’s main shareholder Patricia Industries is a part of Investor AB.

Further information can be found at: www.affibody.com.

Affibody’s Nomination Committee for the 2025 Annual General Meeting